Emerging biomedical and pharmaceutical strategies for the treatment of atherosclerosis: from conventional lipid-lowering therapy to nanomedicine.

IF 1.9 4区医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL

Journal of applied biomedicine Pub Date : 2026-06-01 Epub Date: 2026-05-29 DOI:10.32725/jab.2026.007

Angelika Mysliwiec, Dawid Leksa, Dorota Bartusik-Aebisher, David Aebisher

{"title":"Emerging biomedical and pharmaceutical strategies for the treatment of atherosclerosis: from conventional lipid-lowering therapy to nanomedicine.","authors":"Angelika Mysliwiec, Dawid Leksa, Dorota Bartusik-Aebisher, David Aebisher","doi":"10.32725/jab.2026.007","DOIUrl":null,"url":null,"abstract":"<p><p>Atherosclerotic cardiovascular disease (ASCVD), including myocardial infarction and ischemic stroke, is a leading cause of death and disability worldwide and is expected to rise further by 2030. Once limited to industrialized nations, atherosclerosis has become a global issue due to the epidemiological transition from infectious to chronic metabolic diseases. Lipoproteins (chylomicrons, VLDL, LDL, HDL) and apolipoproteins play key roles in lipid metabolism and atherosclerosis development. Macrophages in plaques influence inflammation and plaque stability, with iron homeostasis also impacting disease progression. Therapies include personalized diets, statins, niacin, omega-3s, fibrates, and antiplatelet agents. Innovative strategies involve natural products and nanotechnology for targeted drug delivery, especially to macrophages and the endothelium, reducing systemic side effects. In summary, advancing therapies based on molecular insights and patient-specific factors are essential to combat this widespread chronic disease.</p>","PeriodicalId":14912,"journal":{"name":"Journal of applied biomedicine","volume":"24 2","pages":"27-48"},"PeriodicalIF":1.9000,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of applied biomedicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.32725/jab.2026.007","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/5/29 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

Abstract

Atherosclerotic cardiovascular disease (ASCVD), including myocardial infarction and ischemic stroke, is a leading cause of death and disability worldwide and is expected to rise further by 2030. Once limited to industrialized nations, atherosclerosis has become a global issue due to the epidemiological transition from infectious to chronic metabolic diseases. Lipoproteins (chylomicrons, VLDL, LDL, HDL) and apolipoproteins play key roles in lipid metabolism and atherosclerosis development. Macrophages in plaques influence inflammation and plaque stability, with iron homeostasis also impacting disease progression. Therapies include personalized diets, statins, niacin, omega-3s, fibrates, and antiplatelet agents. Innovative strategies involve natural products and nanotechnology for targeted drug delivery, especially to macrophages and the endothelium, reducing systemic side effects. In summary, advancing therapies based on molecular insights and patient-specific factors are essential to combat this widespread chronic disease.

查看原文本刊更多论文

新兴的生物医学和药物治疗动脉粥样硬化的策略：从传统的降脂疗法到纳米药物。

动脉粥样硬化性心血管疾病（ASCVD），包括心肌梗死和缺血性中风，是全球死亡和残疾的主要原因，预计到2030年将进一步上升。由于流行病学从传染性疾病向慢性代谢性疾病的转变，动脉粥样硬化一度局限于工业化国家，现已成为一个全球性问题。脂蛋白（乳糜微粒、VLDL、LDL、HDL）和载脂蛋白在脂质代谢和动脉粥样硬化的发展中起关键作用。斑块中的巨噬细胞影响炎症和斑块稳定性，铁稳态也影响疾病进展。治疗包括个体化饮食、他汀类药物、烟酸、ω -3、贝特类药物和抗血小板药物。创新的策略包括天然产物和纳米技术靶向药物递送，特别是巨噬细胞和内皮细胞，减少全身副作用。总之，基于分子洞察力和患者特异性因素的推进疗法对于对抗这种广泛存在的慢性疾病至关重要。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of applied biomedicine PHARMACOLOGY & PHARMACY-

CiteScore

2.40

自引率

7.70%

发文量

审稿时长

>12 weeks

期刊介绍： Journal of Applied Biomedicine promotes translation of basic biomedical research into clinical investigation, conversion of clinical evidence into practice in all medical fields, and publication of new ideas for conquering human health problems across disciplines. Providing a unique perspective, this international journal publishes peer-reviewed original papers and reviews offering a sensible transfer of basic research to applied clinical medicine. Journal of Applied Biomedicine covers the latest developments in various fields of biomedicine with special attention to cardiology and cardiovascular diseases, genetics, immunology, environmental health, toxicology, neurology and oncology as well as multidisciplinary studies. The views of experts on current advances in nanotechnology and molecular/cell biology will be also considered for publication as long as they have a direct clinical impact on human health. The journal does not accept basic science research or research without significant clinical implications. Manuscripts with innovative ideas and approaches that bridge different fields and show clear perspectives for clinical applications are considered with top priority.